Satellos Bioscience Inc (MSCL-X) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Delayed Last Update

Volume

Day Low0.560

Day High0.580

Open:0.580

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Automated Summaries - The Globe and Mail

Closing Bell: Satellos Bioscience Inc up on Wednesday (MSCL)

The Globe and Mail

‘Net-net’ stocks soared in 2023. What is on the list for 2024?

November 21, 2023

AI-generated - The Globe and Mail

Satellos Bioscience: Top 10 Undervalued Biotechnology Industry Stocks (MSCL)

October 29, 2023

AI-generated - The Globe and Mail

Satellos Bioscience: Stocks trading at Less Than Cash Value on TSX-V (MSCL)

October 22, 2023

Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

September 20, 2023

Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

September 8, 2023

Satellos Expands Leadership Team with New CFO Appointment

September 5, 2023

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

August 29, 2023

August Jobs Figure Roll out Next Week in U.S.

August 25, 2023

TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite

August 21, 2023

Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Satellos Bioscience Announces Appointment of Chief Medical Officer

Satellos Bioscience Announces Grant of Stock Options

Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy

Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares

Satellos Bioscience Inc. Announces Pricing of Public Offering

Satellos Bioscience Inc. Announces Public Offering of Common Shares

Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights

Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures

Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million

Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit

Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million

Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy

Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model

February 6, 2023

The Globe and Mail

Satellos Bioscience: Top 10 Undervalued Biotechnology Industry Stocks (MSCL)

December 25, 2022

The Globe and Mail

Satellos Bioscience: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (MSCL)

September 4, 2022

Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.